This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Currently Amended): A compound of the formulae:



or



wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, -S-C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

or a moiety of the formulae:



,



,



,



,



,



, or



;

R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_7 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N-(C_1-C_6\ alkyl)_2$, $-(CH_2)_n-NH-(C_1-C_6\ alkyl)$, $-CF_3$, C_1-C_6 alkyl, C_3-C_5 cycloalkyl, C_1-C_6 alkoxy, $-NH-(C_1-C_6\ alkyl)$, $-N-(C_1-C_6\ alkyl)_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$phenyl, phenyl,-O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, $-(CH_2)_n$-O-phenyl-CH_2-phenyl, $-(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$,the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, $-CF_3$,CO_2H, or -OH;

R_2 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6\ alkyl)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula – L^1-M^1:

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-,

-C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, C(O)C(O)X, $-(CH_2)_n-N-(CH_2)_n-$;

M^1 is selected from the group consisting of:

a) H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl, and benzyl, the cycloalkyl, phenyl and benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, and $-CF_3$, with the proviso that M^1 cannot be H when L^1 is -O-;

b) ~~a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; and~~

~~c)~~ a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n$-C_3-C_6 cycloalkyl, $-(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, $-(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or the groups of:

a) $-(CH_2)_n$-phenyl-O-phenyl, $-(CH_2)_n$-phenyl-CH_2-phenyl, $-(CH_2)_n$-O-phenyl-CH_2-phenyl, $-(CH_2)_n$-phenyl-(O-CH_2-phenyl)$_2$, or a moiety of the formulae:



wherein n is independently selected in each appearance as an integer from 0 to 3, Y is C_3-C_5 cycloalkyl, phenyl, benzyl, napthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these

groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O; or

b) a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$; or

c) a moiety of the formulae:



,


,


,


,


, or


;

wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH_2$, or $-NO_2$; or

d) a moiety of the formula $-L^2-M^2$, wherein:

L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, -S-, -O-, $-SO_2-$, -C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, -C(O)C(O)X;
where X = O, N

M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, or $-CF_3$; or

ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH; or

iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, $-NO_2$, $-NH_2$, -CN, $-CF_3$ or -OH;

n is an integer from 0 to 3;

R_5 is a moiety selected from the formulae $-L^3-M^3$

wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, -S-, -O-, $-SO_2-$, -C(O)-, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$,$-(CH_2)_n-S-(CH_2)_n-$, $-C(Z)-N(R_6)-$, $-C(Z)-N(R_6)-(CH_2)_n-$, $-C(O)-C(Z)-N(R_6)-$, $-C(O)-C(Z)-N(R_6)-(CH_2)_n-$, $-C(Z)-NH-SO_2-$, $-C(Z)-NH-SO_2-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

M^3 is



and n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-CF_3$, -OH, -COOH, $-(CH_2)_n$-COOH, $-(CH_2)_n$-C(O)-COOH, $-C_1$-C_6 alkyl, $-O-C_1$-C_6 alkyl, $-NH(C_1$-C_6 alkyl), or $-N(C_1$-C_6 alkyl$)_2$;

n is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

2 (Previously Amended): A compound of Claim 1 wherein:

R_1 and $R_{1'}$ are independently selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, -S-C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, or -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

M^1 is selected from: H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl and benzyl, the cycloalkyl, phenyl and benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, $-NO_2$, $-NH_2$, -CN, and $-CF_3$, with the proviso that M^1 cannot be H when L^1 is -O-;

R_4 is a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;
or a pharmaceutically acceptable salt thereof.

3 (Previously Amended): A compound of claim 2 wherein R_4 is the moiety:



B and C are phenyl optionally substituted by from 1 to 3 substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$; and R_1, $R_{1'}$, R_2, R_3, R_5, L^1, M^1 and D are as defined in claim 2; or a pharmaceutically acceptable salt thereof.

4 (Previously Amended): A compound of Claim 1 wherein:

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-S-(CH_2)_n-C_3-C_5$ cycloalkyl, $-(CH_2)_n-O-(CH_2)_n-C_3-C_5$ cycloalkyl, or the groups of:

a) a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$; or

b) a moiety of the formula $-L^2-M^2$, wherein L^2 and M^2 are as defined in claim 1;

or a pharmaceutically acceptable salt thereof.

5 (Previously Amended): A compound of Claim 1 wherein:

$R_{1'}$ is H;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, -$(CH_2)_n$-C_3-C_6 cycloalkyl, -$(CH_2)_n$-S-$(CH_2)_n$-C_3-C_5 cycloalkyl, -$(CH_2)_n$-O-$(CH_2)_n$-C_3-C_5 cycloalkyl, or a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

or a pharmaceutically acceptable salt thereof.

6 (Previously Amended): A compound of Claim 1 wherein:

R_1 is selected from H, halogen, -CF_3, -OH, -C_1-C_{10} alkyl, -S-C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -CN, -NO_2, -NH_2, -HN(C_1-C_6), -N(C_1-C_6)$_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NO_2, -NH_2, -CN, -CF_3, or -OH;

or R_1 and $R_{1'}$ are independently a moiety of the formulae:

or a moiety of the formulae:



R_6 and R_7 are as defined in claim 1;

R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, -C_1-C_6 alkyl, -C_3-C_{10} cycloalkyl, -CHO, halogen, $(CH_2)_nC(O)NH_2$ or a moiety of the formula – L^1-M^1:

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, C(O)C(O)X, $-(CH_2)_n-N-(CH_2)_n$;

M^1 is selected from H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -NO_2, -NH_2, -CN, or $-CF_3$;

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-S-(CH_2)_n-C_3-C_5$ cycloalkyl, $-(CH_2)_n-O-(CH_2)_n-C_3-C_5$ cycloalkyl, or a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

or a pharmaceutically acceptable salt thereof.

7 (Previously Amended): A compound of Claim 1 wherein:

R_7 is selected from -OH, $-CF_3$, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NH-(C_1-C_6 alkyl), -N-(C_1-C_6 alkyl)$_2$, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, -CN, C_1-C_6 alkyl, C_1-C_6 alkoxy, -NO_2, -NH_2, $-CF_3$, or -OH;

R_3 is selected from H, -C_1-C_{10} alkyl, -(CH_2)-OH, $(CH_2)_nC(O)NH_2$, -CH_2-O-(C_1-C_6 alkyl, -CH_2-O-CH_2-phenyl, -CH_2-N-(C_1-C_6 alkyl), -CH_2-N-CH_2-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, -CF_3 or -C_1-C_6 alkyl;

X is O or N

n = 0 or 1;

R_4 is a moiety of the formulae -$(CH_2)_n$-A, -$(CH_2)_n$-S-A, or -$(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or -CF_3;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, -CF_3, -OH, -C_1-C_6 alkyl, C_1-C_6 alkoxy, or -NO_2;

R_5 is a moiety selected from the groups of:



wherein L^1 is a bridging or linking moiety selected from a chemical bond, -$(CH_2)_n$-, -$(CH_2)_n$-C(O)-$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-O-$(CH_2)_{n'}$-,-$(CH_2)_{n'}$-S-$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-SO-$(CH_2)_{n'}$-, -$(CH_2)_{n'}$-SO_2-$(CH_2)_{n'}$-, or –$(CH_2)_{n'}$-CH=CH-$(CH_2)_{n'}$-O-;

where n' is an integer from 0 to 5;

R_9 is selected from $-CF_3$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NH(C_1$-C_6 alkyl), or $-N(C_1$-C_6 alkyl)$_2$,

n in each instance is independently selected as an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

8 (Previously Amended): A compound of Claim 1 having the formulae:



wherein:

R_1 is selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, $-S-C_1$-C_{10} alkyl, C_1-C_{10} alkoxy, -CN, $-NO_2$, $-NH_2$, $-HN(C_1$-$C_6)$, $-N(C_1$-$C_6)_2$, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, -CN, $-CF_3$, or -OH;

R_2 is selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_{10} alkyl, C_1-C_{10} alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1$-C_6 alkyl, $-N(C_1$-C_6 alkyl)$_2$, $-N-SO_2-C_1$-C_6 alkyl, or $-SO_2-C_1$-C_6 alkyl;

R_3 is selected from H, $-C_1$-C_{10} alkyl, $-(CH_2)$-OH, $(CH_2)_nC(O)NH_2$, $-CH_2-O-(C_1$-C_6 alkyl), $-CH_2-O-CH_2$-phenyl, $-CH_2-N-(C_1$-C_6 alkyl), $-CH_2-N-CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1$-C_6 alkyl;

n = 0 or 1.

R_4 is a moiety of the formulae $-(CH_2)_n$-A, $-(CH_2)_n$-S-A, or $-(CH_2)_n$-O-A, wherein A is the moiety:



wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, substituents selected from H, halogen, $-CF_3$, -OH, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, or $-NO_2$;

R_5 is a moiety selected from the groups of:



wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n$-, $-(CH_2)_n$-C(O)-$(CH_2)_n$-, $-(CH_2)_n$-O-$(CH_2)_n$-,-$(CH_2)_n$-S-$(CH_2)_n$-, $-(CH_2)_n$-SO-$(CH_2)_n$-, $-(CH_2)_n$-SO_2-$(CH_2)_n$-, or $-(CH_2)_n$-CH=CH-$(CH_2)_n$-O-;

where n = 0-5

R_9 is selected from $-CF_3$, $-C_1$-C_6 alkyl, C_1-C_6 alkoxy, $-NH(C_1$-C_6 alkyl), or $-N(C_1$-C_6 alkyl)$_2$,

n in each instance is independently selected as an integer from 0 to 3,

or a pharmaceutically acceptable salt thereof.

9 (Previously Amended): A compound of Claim 1 having the formulae:



wherein:

R_1 is selected from H, halogen, $-CF_3$, -OH, -CN, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_2 is selected from H, halogen, $-CF_3$, -OH, , -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6$ alkyl$)_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

R_3 is selected from H, $-C_1-C_{10}$ alkyl, $-(CH_2)-OH$, $(CH_2)_nC(O)NH_2$, $-CH_2-O-(C_1-C_6$ alkyl), $-CH_2-O-CH_2$-phenyl, $-CH_2-N-(C_1-C_6$ alkyl), $-CH_2-N-CH_2$-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, $-CF_3$ or $-C_1-C_6$ alkyl;

n = 0 or 1.

R_5 is a moiety selected from the groups of:



wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_{n'}-$, $-(CH_2)_{n'}-C(O)-(CH_2)_{n'}-$, $-(CH_2)_{n'}-O-(CH_2)_{n'}-$,$-(CH_2)_{n'}-S-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO-(CH_2)_{n'}-$, $-(CH_2)_{n'}-SO_2-(CH_2)_{n'}-$, or $-(CH_2)_{n'}-CH=CH-(CH_2)_{n'}-O-$;

n' in each instance is independently selected as an integer from 0 to 5;

or a pharmaceutically acceptable salt thereof.

10 (Original): A compound of Claim 1 which is 4-{[(E)-4-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)-2-butenyl]oxy}benzoic acid or a pharmaceutically acceptable salt thereof.

11 (Original): A compound of Claim 1 which is 4-[2-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)ethoxy]benzoic acid or a pharmaceutically acceptable salt thereof.

12 (Original): A compound of Claim 1 which is 3-{4-[2-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)ethoxy]phenyl}propanoic acid or a pharmaceutically acceptable salt thereof.

13 (Original): A compound of Claim 1 which is 3-(4-{[2-(3-benzhydryl-6-chloro-1H-indol-1-yl)ethyl]sulfonyl}phenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

14 (Original): A compound of Claim 1 which is 4-{[2-(3-benzhydryl-6-chloro-1H-indol-1-yl)ethyl]sulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.

15 (Original): A compound of Claim 1 which is 4-[2-(3-benzhydryl-2-methyl-1H-indol-1-yl)ethoxy]benzoic acid or a pharmaceutically acceptable salt thereof.

16 (Original): A method of inhibiting the phospholipase activity of an enzyme in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

17 (Original): A method of treating or preventing an inflammatory response in a mammal in need thereof, the method comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

18 (Original): The method of Claim 17 wherein the inflammatory response is associated with inflammatory bowel disease.

19 (Original): The method of Claim 17 wherein the inflammatory response is associated with osteoarthritis, psoriatic arthritis or rheumatoid arthritis.

20 (Original): A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.